JP2008156336A5 - - Google Patents

Download PDF

Info

Publication number
JP2008156336A5
JP2008156336A5 JP2007267377A JP2007267377A JP2008156336A5 JP 2008156336 A5 JP2008156336 A5 JP 2008156336A5 JP 2007267377 A JP2007267377 A JP 2007267377A JP 2007267377 A JP2007267377 A JP 2007267377A JP 2008156336 A5 JP2008156336 A5 JP 2008156336A5
Authority
JP
Japan
Prior art keywords
cyclohepta
benzo
pyridin
oxo
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007267377A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008156336A (ja
JP5086762B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2008156336A publication Critical patent/JP2008156336A/ja
Publication of JP2008156336A5 publication Critical patent/JP2008156336A5/ja
Application granted granted Critical
Publication of JP5086762B2 publication Critical patent/JP5086762B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2007267377A 2005-06-23 2007-10-15 チロシンキナーゼインヒビター Expired - Fee Related JP5086762B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US69322905P 2005-06-23 2005-06-23
US60/693,229 2005-06-23
US72906105P 2005-10-21 2005-10-21
US60/729,061 2005-10-21

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008506834A Division JP4119478B1 (ja) 2005-06-23 2006-06-22 チロシンキナーゼインヒビター

Publications (3)

Publication Number Publication Date
JP2008156336A JP2008156336A (ja) 2008-07-10
JP2008156336A5 true JP2008156336A5 (cg-RX-API-DMAC7.html) 2009-07-09
JP5086762B2 JP5086762B2 (ja) 2012-11-28

Family

ID=37478833

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008506834A Expired - Fee Related JP4119478B1 (ja) 2005-06-23 2006-06-22 チロシンキナーゼインヒビター
JP2007267377A Expired - Fee Related JP5086762B2 (ja) 2005-06-23 2007-10-15 チロシンキナーゼインヒビター

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008506834A Expired - Fee Related JP4119478B1 (ja) 2005-06-23 2006-06-22 チロシンキナーゼインヒビター

Country Status (11)

Country Link
US (2) US8207186B2 (cg-RX-API-DMAC7.html)
EP (1) EP1896421B1 (cg-RX-API-DMAC7.html)
JP (2) JP4119478B1 (cg-RX-API-DMAC7.html)
AT (1) ATE524445T1 (cg-RX-API-DMAC7.html)
AU (1) AU2006262172B2 (cg-RX-API-DMAC7.html)
CA (1) CA2611530C (cg-RX-API-DMAC7.html)
DK (1) DK1896421T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20110804T1 (cg-RX-API-DMAC7.html)
RU (1) RU2408584C2 (cg-RX-API-DMAC7.html)
SI (1) SI1896421T1 (cg-RX-API-DMAC7.html)
WO (1) WO2007002254A2 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8207186B2 (en) 2005-06-23 2012-06-26 Merck Sharp & Dohme Corp. Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase MET
JP2009512706A (ja) 2005-10-21 2009-03-26 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼインヒビター
TW200813021A (en) * 2006-07-10 2008-03-16 Merck & Co Inc Tyrosine kinase inhibitors
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
WO2009023846A2 (en) * 2007-08-15 2009-02-19 The Research Foundation Of State University Of New York Methods for heat shock protein dependent cancer treatment
US7893081B2 (en) 2007-12-20 2011-02-22 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2011039527A1 (en) 2009-09-30 2011-04-07 Merck Sharp & Dohme Ltd Formulations for c-met kinase inhibitors
EP2482821A4 (en) 2009-09-30 2013-03-06 Merck Sharp & Dohme CRYSTALLINE HYDROCHLORIDE SALTS FROM C-MET KINASE INHIBITORS
AU2010322800A1 (en) * 2009-11-30 2012-07-12 Proteologics, Ltd. Small pyrimidine derivatives and methods of use thereof
CN101857594B (zh) * 2010-06-18 2013-04-03 南方医科大学 一种四氢吡啶并吲哚类化合物及其制备方法和应用
WO2012003338A1 (en) 2010-07-01 2012-01-05 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
EP2727920B1 (en) 2011-07-29 2016-11-02 FUJIFILM Corporation 1,5-naphthyridine derivative or salt thereof
WO2013131089A2 (en) 2012-03-02 2013-09-06 The Board Of Trustees Of The University Of Illinois Potent anticancer activity via dual compound activation
CN104507479B (zh) 2012-03-06 2017-08-18 伊利诺伊大学评议会 通过联合治疗的半胱天冬酶‑3酶原激活
RU2636234C2 (ru) * 2012-03-06 2017-11-21 Зэ Борд оф Трастиз оф зэ Юниверсити оф Иллинойс Прокаспазная комбинированная терапия при глиобластоме
MX367055B (es) 2012-06-26 2019-08-02 Del Mar Pharmaceuticals El uso de una composición que comprende dianhidrogalactitol, diacetildianhidrogalactitol, y dibromodulcitol, y análogos o derivados de cada uno para el tratamiento de malignidades resistentes a inhibidores de tirosina cinasa.
WO2014150996A1 (en) * 2013-03-15 2014-09-25 Cba Pharma, Inc. Cancer treatment
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
JP6864953B2 (ja) 2014-12-09 2021-04-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Axlに対するヒトモノクローナル抗体
WO2016094361A1 (en) * 2014-12-10 2016-06-16 Southern Research Institute Antiviral agents
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
WO2017161004A1 (en) * 2016-03-15 2017-09-21 University Of South Florida PKCδ INHIBITOR FORMULATIONS AND USES THEREOF CROSS-REFERENCE TO RELATED APPLICATIONS
AU2018368453B2 (en) 2017-11-17 2024-05-30 The Board Of Trustees Of The University Of Illinois Cancer therapy by degrading dual MEK signaling
US12090153B2 (en) 2018-10-05 2024-09-17 The Board Of Trustees Of The University Of Illinois Combination therapy for the treatment of uveal melanoma
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
US20230115865A1 (en) * 2019-10-01 2023-04-13 Sanofi Novel Substituted 6,7-Dihydro-5H-Benzo[7]Annulene Compounds, Processes for Their Preparation and Therapeutic Uses Thereof
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AU2022379973A1 (en) 2021-11-08 2024-06-27 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL132137C (cg-RX-API-DMAC7.html) 1963-04-24
US4826853A (en) 1986-10-31 1989-05-02 Schering Corporation 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use
JP2852659B2 (ja) 1988-03-03 1999-02-03 富山化学工業株式会社 ピペラジン誘導体およびその塩
IE68935B1 (en) 1990-06-22 1996-07-24 Schering Corp Bis-benzo or benzopyrido cyclohepta piperidene piperidylidene and piperazine compounds compositions and methods of use
US6365588B1 (en) 1993-10-15 2002-04-02 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
CN1168133A (zh) 1995-10-16 1997-12-17 协和发酵工业株式会社 三环化合物
CA2264569C (en) 1996-09-13 2003-11-11 Schering Corporation Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
AU4337597A (en) 1996-09-13 1998-04-02 Schering Corporation Substituted benzocycloheptapyridine useful as inhibitors of farnesyl-protein tr ansferase
TR200003580T2 (tr) * 1997-06-17 2002-10-21 Schering Corporation Farnesil protein transferazı'nın önlenmesine mahsus benzo(5,6)siklohepta(1,2-B)piridin türevleri
US7018979B1 (en) 2000-01-26 2006-03-28 Cedars-Sinai Medical Center Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor
JP2003523965A (ja) * 2000-01-26 2003-08-12 シーダース シナイ メディカル センター 異常な脳領域および/または悪性腫瘍に薬剤をデリバリーするためにカリウムチャンネルアゴニストを使用する方法
ATE363473T1 (de) 2001-09-19 2007-06-15 Pharmacia Corp Substituierte pyrazoloverbindungen zur behandlung von entzündungen
AU2003230758A1 (en) 2002-04-02 2003-10-20 Merck And Co., Inc. 5h-benzo(4,5)cyclohepta(1,2-b)pyridine nmda/nr2b antagonists
ES2211315B1 (es) 2002-11-12 2005-10-16 Almirall Prodesfarma, S.A. Nuevos compuestos triciclicos.
JP2006151809A (ja) 2002-12-26 2006-06-15 Ube Ind Ltd ベンゾシクロヘプタピリジン化合物
US8207186B2 (en) 2005-06-23 2012-06-26 Merck Sharp & Dohme Corp. Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase MET
JP2009512707A (ja) 2005-10-21 2009-03-26 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼインヒビター
CA2624656A1 (en) 2005-10-21 2007-05-03 Merck & Co., Inc. Tyrosine kinase inhibitors
JP2009512706A (ja) 2005-10-21 2009-03-26 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼインヒビター
TW200813021A (en) 2006-07-10 2008-03-16 Merck & Co Inc Tyrosine kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2008156336A5 (cg-RX-API-DMAC7.html)
CA2611530A1 (en) Tyrosine kinase inhibitors
AU2019246753B2 (en) Novel compounds and compositions for inhibition of FASN
ES2708211T3 (es) 3-amino-1,5,6,7-tetrahidro-4H-indol-4-onas
JP7112567B2 (ja) 二環式betブロモドメイン阻害剤及びその使用
AU2017277732B2 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
JP5134548B2 (ja) 過剰増殖性疾患の処置のためのErbBI型受容体チロシンキナーゼ阻害剤としてのN4−フェニルキナゾリン−4−アミン誘導体および関連化合物
CA2781287C (en) Compounds and methods for kinase modulation, and indications therefor
AU2011242778B2 (en) Compounds and methods for kinase modulation, and indications therefor
KR102007056B1 (ko) 과증식성 질환 치료시 Bub1 키나제 저해제로 사용하기 위한 치환된 벤질인다졸
AU2005278292B2 (en) Novel substituted imidazole derivatives
AU2014373773C1 (en) Compounds and methods of use
HRP20170349T1 (hr) Novi derivati pirola, postupak njihove priprave i farmaceutski pripravci koji ih sadrže
CA3067765A1 (en) Imidazo[1,2-a]pyrazine modulators of the adenosine a2a receptor
MX2007010326A (es) Compuestos de imidazo(1,2-a)piridina como inhibidores de vegf-r2.
RU2014119244A (ru) Гетероциклические соединения и способы их использования
JP2010513495A (ja) 新規なjnk阻害剤
CA3107365A1 (en) Pyrazine compounds and uses thereof
JP2011529504A5 (cg-RX-API-DMAC7.html)
WO2016006706A1 (ja) テトラヒドロピラ二ルメチル基を有するピリドン誘導体
CN119451951A (zh) 用于抑制kif18a的化合物
JP2019500389A (ja) 窒素含有縮合複素環化合物、製造方法、中間体、組成物および使用
CA3239992A1 (en) Compounds and use thereof as hdac6 inhibitors
CN107567445A (zh) 可用作哺乳动物酪氨酸激酶ror1活性抑制剂的2‑苯基‑3h‑咪唑并[4,5‑b]吡啶衍生物
EP3390401A1 (en) Hetero-1,5,6,7-tetrahydro-4h-indol-4-ones